Core Viewpoint - The approval of NDA for ABSK021 marks a significant milestone for the company, transitioning from clinical research to commercialization, indicating its full-cycle innovation capability from development to market launch [1] Group 1: Product Approval - The National Medical Products Administration (NMPA) has approved the NDA for ABSK021, intended for the treatment of symptomatic adult patients with tenosynovial giant cell tumor (TGCT) that may lead to functional limitations or serious complications [1] - The FDA has also formally accepted the NDA for ABSK021 for systemic treatment of TGCT patients [1] Group 2: Market Impact - Following the news, the company's stock price increased by 6.29%, reaching HKD 13.34, with a trading volume of HKD 22.93 million [1] - According to Zhongtai Securities, the approval signifies the company's transition to the commercialization phase, enhancing its potential for stable cash flow through its collaboration with Merck [1] Group 3: Long-term Efficacy - Long-term follow-up data indicates that the response rate of ABSK021 improves over time, supporting its therapeutic potential [1]
和誉-B午后涨超6% ABSK021有望中美上市 公司正式进入商业化阶段